Logix Biosciences has partnered with Mayo Clinic to share knowledge to produce precision therapeutics for unmet needs in its focus areas of allergy relief, infectious disease protection, and antimicrobial resistance.
The partnership will leverage Logix Biosciences' expertise in drug development and Mayo Clinic's research capabilities to develop Logix's pipeline, including an active ingredient derived from medical-grade manuka honey. The aim is to advance the clinical development of the ingredient into the lead drug candidate. Studies are planned to commence immediately with preclinical work. Subject to necessary funding, clinical trials are expected to be initiated later this year.
Logix Biosciences specializes in nasal immune modulation, focusing on developing novel therapeutics for underserved medical needs such as allergy relief, mutating infectious diseases, and bacterial resistance. The company’s non-drug OTC nasal spray is designed to clean allergens and particulate matter from the nasal cavities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.